Evidence map›Paper›PMID 39087021›Full record

ArticleFrontiers in oncology2024

Emerging cancer disease burden in a rural sub-Saharan African population: northeast Nigeria in focus.

Uchenna S Ezenkwa, Aliyu Ibrahim Lawan, Musa Abubakar Garbati, Dauda E Suleiman, Dauda A Katagum, Abba Kabir, Adamu Isa Adamu, Abubakar Kolomi Modu, Olaniyi David Olanrewaju, Rufai Abdu Dachi and 8 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Uchenna S Ezenkwa *Department of Histopathology, Federal University of Health Sciences Azare, Azare, Bauchi, Nigeria.
Aliyu Ibrahim Lawan *Department of Histopathology, College of Medical Sciences, Gombe State University, Gombe, Gombe, Nigeria.
Musa Abubakar Garbati *Directorate of Research, Innovation and Development, Federal University of Health Sciences Azare, Azare, Bauchi, Nigeria.
Dauda E Suleiman *Department of Histopathology, College of Medical Sciences, Abubakar Tafawa Balewa University, Bauchi, Bauchi, Nigeria.
Dauda A Katagum *Department of Obstetrics and Gynaecology, Federal University of Health Sciences Azare, Azare, Bauchi, Nigeria.
Abba Kabir *Department of Histopathology, College of Medical Sciences, University of Maiduguri, Maiduguri, Borno, Nigeria.
Adamu Isa Adamu *Department of Histopathology, Yobe State University, Damaturu, Yobe, Nigeria.
Abubakar Kolomi Modu *Department of Pathology, Federal Medical Centre Nguru, Nguru, Yobe, Nigeria.
Olaniyi David OlanrewajuDepartment of Haematology and Blood Transfusion, Federal University of Health Sciences, Azare, Nigeria.
Rufai Abdu DachiDepartment of Haematology, Abubakar Tafawa Balewa University, Bauchi, Bauchi, Nigeria.
Yusuf Mohammed Abdullahi *Department of Histopathology, College of Medical Sciences, Gombe State University, Gombe, Gombe, Nigeria.
Muhammed Alkali *Department of Medicine, Federal University of Health Sciences, Azare, Bauchi, Nigeria.
Danladi Adamu Bojude *Community Oncology and Epidemiology, Gombe State University, Gombe, Gombe, Nigeria.
Hadiza Abdullahi Usman *Department of Obstetrics and Gynecology, Federal Medical Centre Nguru, Nguru, Yobe, Nigeria.
Ayodele Omotoso *Division of Gynecologic Oncology, Department of Obstetrics, Gynaecology and Reproductive Sciences, Sylvester Comprehensive Cancer Centre, University of Miami Miller School of Medicine, Miami, FL, United States.
Matthew Schlumbrecht *Division of Gynecologic Oncology, Department of Obstetrics, Gynaecology and Reproductive Sciences, Sylvester Comprehensive Cancer Centre, University of Miami Miller School of Medicine, Miami, FL, United States.
Sophia H L George *Division of Gynecologic Oncology, Department of Obstetrics, Gynaecology and Reproductive Sciences, Sylvester Comprehensive Cancer Centre, University of Miami Miller School of Medicine, Miami, FL, United States.
Bala Mohammed Audu *Department of Obstetrics and Gynaecology, Federal University of Health Sciences Azare, Azare, Bauchi, Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Sub-Saharan Africa (SSA) is plagued by myriads of diseases, mostly infectious; but cancer disease burden is rising among non-communicable diseases. Nigeria has a high burden of cancer, however its remote underserved culturally-conserved populations have been understudied, a gap this study sought to fill. Methods: This was a cross-sectional multi-institutional descriptive study of histologically diagnosed cancers over a four-year period (January 2019-December 2022) archived in the Departments of Pathology and Cancer Registries of six tertiary hospitals in the northeast of Nigeria. Data obtained included age at diagnosis, gender, tumor site and available cancer care infrastructure. Population data of the study region and its demographics was obtained from the National Population Commission and used to calculate incident rates for the population studied. Results: A total of 4,681 incident cancer cases from 2,770 females and 1,911 males were identified. The median age at diagnosis for females was 45 years (range 1-95yrs), and 56 years (range 1-99yrs) for males. Observed age-specific incidence rates (ASR) increased steadily for both genders reaching peaks in the age group 80 years and above with the highest ASR seen among males (321/100,000 persons) compared to females (215.5/100,000 persons). Breast, cervical, prostatic, colorectal and skin cancers were the five most common incident cancers. In females, breast, cervical, skin, ovarian and colorectal cancers were the top five malignancies; while prostate, haematolymphoid, skin, colorectal and urinary bladder cancers predominated in men. Conclusion: Remote SSA communities are witnessing rising cancer disease burden. Proactive control programs inclusive of advocacy, vaccination, screening, and improved diagnostics are needed.

Indexed as

age-specific ratecancer burdencancer care disparitynortheast Nigeriasub-Saharan Africa

Identifiers

PMID39087021
PMCPMC11288908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.